ImmunityBio's (IBRX) supplemental biologics license application for Anktiva in combination with Bacillus Calmette-Guerin in patients with bladder cancer with papillary disease has been accepted for review by the US Food and Drug Administration, the company said late Tuesday.
The filing was supported by results from a phase 2/3 trial, which met its primary endpoint with a 12-month disease-free survival rate of 58.2%, ImmunityBio said.
The regulator has set a Prescription Drug User Fee Act target action date of Jan. 6, 2027, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments